The primary objective of the trial is to estimate the effects of allocation to irbesartan, or
doxycycline, or a combination of both irbesartan and doxycycline, compared with placebo, on
measures of elastic function of the aorta in people with the Marfan syndrome and enlargement
of the aorta.